Russell Investments Group Ltd. Buys 217,877 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Russell Investments Group Ltd. increased its ownership in Amneal Pharmaceuticals by 81.9% during the first quarter, now holding approximately 0.16% of the company valued at $4.03 million.
• Other institutional investors, including Vanguard Group Inc. and Dimensional Fund Advisors LP, also raised their stakes, collectively indicating growing confidence in Amneal Pharmaceuticals.
• Amneal Pharmaceuticals has received a consensus rating of "Buy" from analysts, with a price target of $11.60, reflecting optimism about the company's future performance.

Russell Investments Group Ltd. grew its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 81.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 483,804 shares of the company's stock after acquiring an additional 217,877 shares during the period. Russell Investments Group Ltd. owned 0.16% of Amneal Pharmaceuticals worth $4,035,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Janney Montgomery Scott LLC raised its position in Amneal Pharmaceuticals by 26.9% in the 1st quarter. Janney Montgomery Scott LLC now owns 19,350 shares of the company's stock worth $162,000 after purchasing an additional 4,100 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Amneal Pharmaceuticals by 53.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 60,567 shares of the company's stock worth $508,000 after acquiring an additional 21,079 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Amneal Pharmaceuticals by 45.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 318,420 shares of the company's stock worth $2,522,000 after acquiring an additional 99,866 shares during the last quarter. California State Teachers Retirement System raised its holdings in Amneal Pharmaceuticals by 10.3% during the 4th quarter. California State Teachers Retirement System now owns 131,713 shares of the company's stock worth $1,043,000 after purchasing an additional 12,282 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Amneal Pharmaceuticals by 209.2% during the 4th quarter. BNP Paribas Financial Markets now owns 168,194 shares of the company's stock worth $1,332,000 after purchasing an additional 113,796 shares during the last quarter. Institutional investors own 31.82% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Wall Street Zen cut Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. The Goldman Sachs Group initiated coverage on shares of Amneal Pharmaceuticals in a research note on Friday, June 6th. They set a "buy" rating and a $12.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $11.60.

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX traded down $0.02 during trading hours on Wednesday, reaching $9.37. 368,765 shares of the company's stock were exchanged, compared to its average volume of 1,673,800. The company's 50-day moving average is $8.43 and its two-hundred day moving average is $8.03. Amneal Pharmaceuticals, Inc. has a one year low of $6.68 and a one year high of $9.79. The company has a market capitalization of $2.94 billion, a price-to-earnings ratio of 937.44 and a beta of 1.11.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. Research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In related news, EVP Jason B. Daly sold 22,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total value of $199,100.00. Following the completion of the transaction, the executive vice president owned 10,606 shares of the company's stock, valued at approximately $95,984.30. This trade represents a 67.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Andrew S. Boyer sold 279,244 shares of the firm's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the completion of the transaction, the executive vice president directly owned 152,426 shares of the company's stock, valued at approximately $1,429,755.88. This trade represents a 64.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold 577,206 shares of company stock valued at $5,405,265 in the last ninety days. 17.45% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.